Low doses of recombinant interferon alpha 2b were used to treat two patients with Kaposi's sarcoma not associated with AIDS. Clinical benefit was obtained after a few months in both cases. In one case dynamic telethermography demonstrated regression of the disease after 9 months of treatment. No serious side-effects were observed during interferon administration. We conclude that recombinant interferon alpha 2b could be considered a treatment of choice for Kaposi's sarcoma not associated with AIDS.
ASJC Scopus subject areas